Cure Pharmaceutical Financing
Cure Pharmaceutical Corp, Corporation just released form D regarding $6.03 million debt financing. This is a new filing. Cure Pharmaceutical was able to fundraise $6.03 million. That is 100.00% of the financing offer. The total fundraising amount was $6.03 million. The financing document was filed on 2016-10-31. The reason for the financing was: In addition to the sales commission described above, the Company is required to issue warrants to purchase an aggregate of 141,142 shares of common stock of the Company at an exercise price of $1.00 per share..
Cure Pharmaceutical is based in California. The firm’s business is Pharmaceuticals. The form was filed by Mark Udell CFO. The company was incorporated more than five years ago. The filler’s address is: 1620 Beacon Place, Oxnard, Ca, California, 93033. Rob Davidson is the related person in the form and it has address: 1620 Beacon Place, Oxnard, Ca, California, 93033. Link to Cure Pharmaceutical Filing: 000155428916000008.
Analysis of Cure Pharmaceutical Offering
On average, companies in the Pharmaceuticals sector, sell 60.90% of the total offering amount. Cure Pharmaceutical sold 100.00% of the offering. Could this mean that the trust in Cure Pharmaceutical is high? The average investment offering size for companies in the Pharmaceuticals industry is $556,000. The total amount raised is 985.25% bigger than the average for companies in the Pharmaceuticals sector. The minimum investment for this financing is set at $0. If you know more about the reasons for the fundraising, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Cure Pharmaceutical Also
The Form D signed by Mark Udell might help Cure Pharmaceutical Corp’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.